Journal of Allergy and Infectious Diseases

Dar BA, et al., J Allergy Infect Dis. 2026;7(1):5-9.

Commentary

Precision targeting of the kinome: clinical progress, biological complexities, and future directions of protein kinase inhibitors

Bashir Ahmad Dar[1,*], Asif Hamid Dar[2], Shamim Ahmad Dar[3]

[1]Department of Chemistry, Government Degree College, Uri, Baramulla, 193123, J&K, India

[2]Department of Botany, Government Degree College, Uri, Baramulla, 193123, J&K, India

[3]Department of Zoology, Government Degree College Sogam 192231, India

*Author for correspondence: Email: bashir_15_dar@yahoo.com

Received date: December 08, 2025
Accepted date: December 29, 2025

Introduction

Protein kinases are at the core of cellular communication, and they essentially control cell survival, metabolism, immune activation, and proliferation, among other things, through reversible phosphorylation [1]. The dysregulation of kinase signaling has been identified as a key driver at the molecular level of cancer, autoimmune diseases, chronic inflammations, cardiovascular diseases, and infectious pathogenesis [2,3]. In the span of 20 years, inhibitors of protein kinases have become one of the most dominant agents in the field of targeted therapeutics [4]. After being initially planned for use against oncogenic kinases, these pharmaceutical agents have now extended their clinical relevance far beyond cancer into allergy, immunology, and inflammation [5]. This article synthesizes the recent advances in the development of protein kinase inhibitors, studies new clinical applications, and evaluates the existing limitations, such as signaling redundancy, resistance, toxicity, and economic barriers. It focuses on the precision kinome targeting concept, adaptive combination strategies, and systems-level intervention. This paper does not duplicate the work of other reviewers but rather serves as an expert narrative on the current state and future direction of protein kinase inhibition.

Protein Phosphorylation and the Kinome in Cellular Regulation and Disease

Protein phosphorylation is a prime example of a very powerful regulatory mechanism in the realm of biology. Over five hundred protein kinases, which make up the human genome, are responsible for the aforementioned cellular functions through the site-specific phosphorylation of substrate proteins. These regulatory functions include cellular proliferation, differentiation, metabolism, cytoskeletal dynamics, immune activation, stress responses, and apoptosis [6–8]. The whole network, called the kinome, which results from these interactions, does not work as a simple cascade but rather as a very complex system that is highly interconnected and dynamically adaptive. The constant disturbance caused to this system by mutation, overexpression, or aberrant activation at the molecular level is the basis of most human diseases—notably cancer, autoimmune disorders, chronic inflammation, cardiovascular pathology, and new infectious syndromes [9–11].

Early Breakthroughs in the Discovery of Kinase Inhibitors

The kinase inhibition clinical era was initiated by the success of Imatinib in chronic myeloid leukemia, thus demonstrating for the first time that the selective blocking of a disease-driving kinase could bring about a profound and lasting therapeutic benefit [12,13]. This event essentially changed the face of drug discovery by affirming kinases as targets that could be engaged by drugs, and thereby, a new era of PKI generations' rapid development was started. Currently, the total number of kinase-targeted medications approved by different regulatory authorities globally is over 80, and there are hundreds of candidates in clinical trials [14,15].

The majority of first-generation PKIs were mainly ATP-competitive inhibitors with limited selectivity and some off-target activities. Nevertheless, the improvements in areas such as structural biology, crystallography, cryo-electron microscopy, and computational chemistry have enabled the rational creation of the next-generation inhibitors that utilize the minor conformational differences between the active and inactive kinase states for their action [16–18]. Contemporary drugs can access the allosteric regulatory sites, be covalently and irreversibly attached to the catalytic residues, and are also designed with the best pharmacokinetics and selectivity in mind [19–21]. Thus, fewer kinase cross-reactivities that cause unwanted effects and systemic toxicities are possible, and, at the same time, the therapeutic window for applications in chronic diseases has been extended considerably.

Scope of PKI's in Oncological Signaling Pathways

Even though oncology is still the major area of clinical PKI achievement, kinase inhibition has massively extended its frontiers to immunology and inflammatory medicine. Intracellular kinases orchestrate immune activation at nearly every stage, e.g., antigen receptor signaling, cytokine production, lymphocyte proliferation, and innate immune cell recruitment [22–24]. Targeting these intracellular signaling mediators gives a different therapeutic paradigm than that of extracellular cytokine neutralization by biologic antibodies. The shift towards this approach is demonstrated by the clinical efficacy of Janus kinase (JAK) inhibitors in autoimmune and inflammatory diseases. JAK inhibitors have illustrated quick and potent anti-inflammatory capabilities in rheumatoid arthritis, ulcerative colitis, psoriatic arthritis, and atopic dermatitis by inhibiting multiple cytokine receptor pathways at once [25–27]. Unfortunately, the extensive intracellular action also comes with a higher risk of infection, thromboembolic events, and metabolic disturbances; thus, the need for the efficacy-systemic immunosuppression trade-off to be carefully balanced [28–30].

Scope of PKI's in Immunomodulation

Another area where kinase blockage is obtaining a positive trend is that of allergy and airway inflammatory disease. The kinases SYK, BTK, and PI3K are substantially involved in IgE-mediated mast-cell activation, eosinophil survival, airway smooth-muscle contraction, and epithelial barrier function [31–33]. The inhibition of these mechanisms not only neutralizes the downstream mediators but also provides the opportunity to completely turn off the intracellular origin of allergic inflammation. However, in contrast to cancer, where therapeutic risk is expected in life-threatening conditions, allergic disorders come with much higher safety expectations. The long-term use of kinase suppressants in stable allergic patients demands excellent selectivity along with rigorous post-marketing surveillance.

Role of Protein Kinase Inhibitors in Host-Pathogen Molecular Crosstalk

One of the most promising areas of PKI research is the notion of host-directed kinase inhibition in infectious diseases. Numerous viruses, bacteria, and intracellular pathogens use kinase pathways in their host cells to facilitate entry, replication, immune evasion, and transmission [34–36]. Theoretically, blocking the host kinases instead of microbial enzymes yields benefits such as a lower chance of pathogen resistance development and the opportunity to control hyper-inflammatory immune responses simultaneously. The approach has received much attention, particularly in the case of infections resulting in cytokine release dysregulation. However, the targeting of host kinases is associated with biological risks as well since these enzymes are also indispensable for protective immune defense and tissue homeostasis.

Protein Kinases Depict Redundancy

Biological complexity of kinase signaling, which was very well solved biologically in the lab by PKIs therapy, puts fundamental limitations on these therapies in the clinical setting. The most formidable of these is signaling redundancy. The researchers found out that among hundreds of kinases that participate in overlapping pathways, the inhibition of one node leads the cell to find a different pathway by itself so that it tries to preserve the function all in all [37–39]. The plasticity of this network gives the diseased cells a strong ability to adapt, which makes it very hard to achieve pharmacologic suppression for a long time. Therapeutic resistance to kinase inhibitors is, therefore, not an exceptional clinical problem but rather a biological property of the signaling networks under pressure.

Drug resistance may occur through various mechanisms such as the occurrence of secondary point mutations in the kinase domain, duplication of the target gene, activation of bypass signaling pathways, epigenetic remodeling, and the microenvironment providing survival cues [40–43]. Most of these mechanisms are present simultaneously and co-evolve during therapy. The clinical consequence of this is that initial dramatic responses to single-agent PKIs are frequently followed by disease relapse. This fact has caused the scientific community to reconsider the rationale of single-target inhibition, which led to the emergence of combination therapy and adaptive treatment strategies.

Protein Kinase Inhibitors Impose an Economic Burden to Developing Nations

Toxicity is still the price one has to pay for kinase inhibition. Kinases are the molecules that regulate pathological signaling as well as essential physiological processes such as hematopoiesis, glucose metabolism, vascular integrity, and mitochondrial function [44–46]. Even highly selective inhibitors may influence several kinases at therapeutic concentrations, thus leading to adverse effects such as cardiotoxicity, hepatotoxicity, cytopenias, endocrine dysfunction, and opportunistic infections. All these risks together are more pronounced when PKIs are given chronically, as it is more and more the case in the treatment of autoimmune and inflammatory diseases.

Moreover, poor biomarkers make the job of clinicians even more difficult. Although genomic testing has made patient stratification more accurate, single mutations or isolated signaling readouts rarely reflect the real complexity of kinase dependency [47,48]. Both tumors and inflammatory tissues may have changing and heterogeneous signaling profiles that also change under therapeutic pressure. This has caused the demand for multi-omic profiling platforms that combine genomics, transcriptomics, proteomics, and metabolomics to be used for creating dynamic predictive models of kinase vulnerability [49,50].

Furthermore, the variability between different individuals becomes an additional challenge for translation. Differences in drug absorption, metabolism, transporter expression, immune competence, microbiome composition, and comorbid diseases can robustly impact PKI response and toxicity [51–53]. These are

only partly reflected in clinical trials and are often the reason for the difference between the trial results and real-life effectiveness. Precision kinase therapy thus requires not only molecular targeting but also personalized pharmacology.

Rational Combination Therapy to Overcome PKI-Related Clinical Flaws

New strategies to get past these restrictions mainly point to one basic idea—rational combination therapy. PKIs are now combined with immune checkpoint inhibitors, epigenetic modulators, metabolic drugs, and proteostasis regulators, so they can shut down the compensatory survival pathways that lead to resistance before resistance even has a chance to develop [54–56]. Although combination treatment has made the response more durable in a number of cancers, it has also created more overlapping toxicities, which further increase the need for precise dosing, optimized scheduling, and continuous biomonitoring.

Another solution that looks promising in targeting the cause of systemic toxicity is the use of targeted drug-delivery systems. Nanoparticle carriers, antibody-drug conjugates, and tissue-specific prodrug systems all work to concentrate kinase inhibitors in the diseased tissues while at the same time limiting the exposure of healthy organs to these drugs [57–59]. The joining of nanotechnology and kinase pharmacology is especially attractive in cancer and inflammatory diseases, where the affected tissues often have unique vascular or microenvironmental features that can be used for the selective accumulation of the drug.

Scope of AI in Protein Kinase Research

Artificial intelligence is substantially changing how kinase drug discovery is performed. Machine learning techniques allow large-scale predictions of kinase-inhibitor interactions and are also used in resistance mutation forecasting, efficient virtual screening of huge chemical libraries, and data-driven drug repurposing [60–62]. Computational platforms, in turn, are getting closely linked with clinical outcome data to facilitate therapeutic decision-making in real-time and guide adaptive treatment algorithms. In the context of precision medicine, PKIs are no longer seen as mere molecular inhibitors but as signaling modulators. Precision kinase therapy implies that drug choice, dosing, and combination can be changed on-the-fly, based on the continuous molecular monitoring of the disease signaling flux [63]. Such a transformation implies that not only advanced diagnostic tools will be needed but also digital health systems, which would be capable of integrating multi-omic and clinical data streams. Apart from the scientific and clinical aspects, the kinase inhibitor therapy is surrounded by deep economic and ethical issues. The high price of a long-term treatment makes a significant financial burden both on the patients and healthcare systems, which, in turn, affects low- and middle-income countries the most [64]. Limited access to molecular diagnostics, inequities in reimbursement policy, and the ever-increasing drug prices are some of the factors that consistently raise the question about the global fairness of access to precision medicine. Solving these issues will indeed require international strategies working in harmony, such as biosimilar development, tiered pricing, and public–private partnerships. In the subsequent years, the study of kinase inhibitors would be less about isolated pathway models and more about systems biology. Context-dependent targeting, host-directed anti-infective kinase therapy, integration with cell and gene-based treatments, and digital biomonitoring of therapeutic response are some of the innovations that have the potential to change the PKI landscape [65]. The therapeutic objective is no longer simple pathway blockade but intelligent reprogramming of pathological signaling networks.

Future Perspectives

Ultimately, protein kinase inhibitors have become one of the most potent and diverse drug classes in the history of medicine. Their influence is expanding at a rapid pace far beyond the realm of cancer to immunology, inflammation, allergy, and infectious disease biology. With the incredible progress made, there are still challenges such as resistance, toxicity, network redundancy, biomarker limitations, and economic hurdles that limit their potential. The upcoming era of kinase therapeutics will be hinged on molecular precision integration, adaptive treatment design, artificial intelligence, and global accessibility. It is only by such multi-dimensional innovation that the full promise of kinase inhibition can eventually be achieved.

References

1. Akinseye OR. Role of Protein Kinases in Cellular Signaling. In: Karamanos Y, Editor. Metabolism Annual Volume 2024. London: IntechOpen; 2024 Dec 19.
2. Cucu I. Signaling pathways in inflammation and cardiovascular diseases: an update of therapeutic strategies. Immuno. 2022 Nov 11;2(4):630–50.
3. Sarkar N, Singh A, Kumar P, Kaushik M. Protein kinases: Role of their dysregulation in carcinogenesis, identification and inhibition. Drug Res (Stuttg). 2023 Apr;73(4):189–99.
4. Roskoski R Jr. A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol Res. 2015 Oct;100:1–23.
5. Castelo-Soccio L, Kim H, Gadina M, Schwartzberg PL, Laurence A, O'Shea JJ. Protein kinases: drug targets for immunological disorders. Nat Rev Immunol. 2023 Dec;23(12):787–806.
6. Johnson LN. The regulation of protein phosphorylation. Biochem Soc Trans. 2009 Aug;37(Pt 4):627–41.
7. Ruperez P, Gago-Martinez A, Burlingame AL, Oses-Prieto JA. Quantitative phosphoproteomic analysis reveals a role for serine and threonine kinases in the cytoskeletal reorganization in early T cell receptor activation in human primary T cells. Mol Cell Proteomics. 2012 May;11(5):171–86.
8. Wang T, Zhang X, Li JJ. The role of NF-kappaB in the regulation of cell stress responses. Int Immunopharmacol. 2002 Oct;2(11):1509–20.
9. Alganem K, Hamoud AR, Creeden JF, Henkel ND, Imami AS, Joyce AW, et al. The active kinome: The modern view of how active protein kinase networks fit in biological research. Curr Opin Pharmacol. 2022 Feb;62:117–29.
10. Graves LM, Duncan JS, Whittle MC, Johnson GL. The dynamic nature of the kinome. Biochem J. 2013 Feb 15;450(1):1–8.
11. Borgo C, D'Amore C, Sarno S, Salvi M, Ruzzene M. Protein kinase CK2: a potential therapeutic target for diverse human diseases. Signal Transduct Target Ther. 2021 May 17;6(1):183.
12. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005 Apr 1;105(7):2640–53.
13. Herrmann O, Kuepper MK, Bütow M, Costa IG, Appelmann I, Beier F, et al. Infliximab therapy together with tyrosine kinase inhibition

targets leukemic stem cells in chronic myeloid leukemia. BMC Cancer. 2019 Jul 4;19(1):658.

14. Cohen P, Cross D, Jänne PA. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov. 2021 Jul;20(7):551–69.
15. Attwood MM, Fabbro D, Sokolov AV, Knapp S, Schiöth HB. Trends in kinase drug discovery: targets, indications and inhibitor design. Nat Rev Drug Discov. 2021 Nov;20(11):839–61.
16. Li J, Gong C, Zhou H, Liu J, Xia X, Ha W, et al. Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives. Int J Mol Sci. 2024 May 17;25(10):5489.
17. Baldi S, Long N, Ma S, Liu L, Al-Danakh A, Yang Q, et al. Advancements in Protein Kinase Inhibitors: From Discovery to Clinical Applications. Research (Wash D C). 2025 Jun 21;8:0747.
18. Modi V, Dunbrack RL Jr. Defining a new nomenclature for the structures of active and inactive kinases. Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):6818–27.
19. Nussinov R, Tsai CJ. The design of covalent allosteric drugs. Annu Rev Pharmacol Toxicol. 2015;55:249–67.
20. Wenthur CJ, Gentry PR, Mathews TP, Lindsley CW. Drugs for allosteric sites on receptors. Annu Rev Pharmacol Toxicol. 2014;54:165–84.
21. Chatzigoulas A, Cournia Z. Rational design of allosteric modulators: Challenges and successes. Wiley Interdisciplinary Reviews: Computational Molecular Science. 2021 Nov;11(6):e1529.
22. Patras de Campaigno E, Bondon-Guitton E, Laurent G, Montastruc F, Montastruc JL, Lapeyre-Mestre M, et al. Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics. Br J Clin Pharmacol. 2017 Jul;83(7):1544–55.
23. Castelo-Soccio L, Kim H, Gadina M, Schwartzberg PL, Laurence A, O'Shea JJ. Protein kinases: drug targets for immunological disorders. Nat Rev Immunol. 2023 Dec;23(12):787–806.
24. Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018 May;17(5):353–77.
25. Yi M, Li T, Niu M, Zhang H, Wu Y, Wu K, et al. Targeting cytokine and chemokine signaling pathways for cancer therapy. Signal Transduct Target Ther. 2024 Jul 22;9(1):176.
26. Andreakos E. Targeting cytokines in autoimmunity: new approaches, new promise. Expert Opin Biol Ther. 2003 Jun;3(3):435–47.
27. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017 Dec;16(12):843–62.
28. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab. 2009 Jun;10(5):470–81.
29. Kotyla PJ, Engelmann M, Giemza-Stokłosa J, Wnuk B, Islam MA. Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role? Int J Mol Sci. 2021 Feb 28;22(5):2449.
30. Scott IC, Hider SL, Scott DL. Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk? Drug Saf. 2018 Jul;41(7):645–53.
31. Wong WS, Leong KP. Tyrosine kinase inhibitors: a new approach for asthma. Biochim Biophys Acta. 2004 Mar 11;1697(1-2):53–69.
32. Wong BR, Grossbard EB, Payan DG, Masuda ES. Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin Investig Drugs. 2004 Jul;13(7):743–62.
33. Iyer AS. Role of TEC family kinases ITK and BTK in FcεRI mediated mast cell signaling. The Pennsylvania State University; 2008.
34. Zumla A, Rao M, Wallis RS, Kaufmann SH, Rustomjee R, Mwaba P, et al. Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. Lancet Infect Dis. 2016 Apr;16(4):e47–63.
35. Schwegmann A, Brombacher F. Host-directed drug targeting of factors hijacked by pathogens. Sci Signal. 2008 Jul 22;1(29):re8.
36. Mahon RN, Hafner R. Immune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis: An Opportunity to Apply Precision Medicine Innovations to Infectious Diseases. Clin Infect Dis. 2015 Oct 15;61Suppl 3(Suppl 3):S200–16.
37. Li J, Gong C, Zhou H, Liu J, Xia X, Ha W, et al. Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives. Int J Mol Sci. 2024 May 17;25(10):5489.
38. Sun C, Bernards R. Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. Trends Biochem Sci. 2014 Oct;39(10):465–74.
39. Mordret G. MAP kinase kinase: a node connecting multiple pathways. Biol Cell. 1993;79(3):193–207.
40. Haider T, Pandey V, Banjare N, Gupta PN, Soni V. Drug resistance in cancer: mechanisms and tackling strategies. Pharmacol Rep. 2020 Oct;72(5):1125–51.
41. Kim P, Li H, Wang J, Zhao Z. Landscape of drug-resistance mutations in kinase regulatory hotspots. Brief Bioinform. 2021 May 20;22(3):bbaa108.
42. Zhang W, Li S, Li C, Li T, Huang Y. Remodeling tumor microenvironment with natural products to overcome drug resistance. Front Immunol. 2022 Nov 10;13:1051998.
43. Karami Fath M, Azargoonjahromi A, Kiani A, Jalalifar F, Osati P, Akbari Oryani M, et al. The role of epigenetic modifications in drug resistance and treatment of breast cancer. Cell Mol Biol Lett. 2022 Jun 28;27(1):52.
44. Grossman M, Adler E. Protein Kinase Inhibitors-Selectivity or Toxicity?. In: Singh RK, Editor. Protein Kinases-Promising Targets for Anticancer Drug Research. London: IntechOpen; 2021 Jul 12.
45. Scheijen B, Griffin JD. Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene. 2002 May 13;21(21):3314–33.
46. Kotrasová V, Keresztesová B, Ondrovičová G, Bauer JA, Havalová H, Pevala V, et al. Mitochondrial Kinases and the Role of Mitochondrial Protein Phosphorylation in Health and Disease. Life (Basel). 2021 Jan 23;11(2):82.
47. Frangogiannis NG. Biomarkers: hopes and challenges in the path from discovery to clinical practice. Transl Res. 2012 Apr;159(4):197–204.
48. Attwood MM, Fabbro D, Sokolov AV, Knapp S, Schiöth HB. Trends in kinase drug discovery: targets, indications and inhibitor design. Nat Rev Drug Discov. 2021 Nov;20(11):839–61.
49. Hölzel M, Bovier A, Tüting T. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer. 2013 May;13(5):365–76.
50. Mukherjee A, Abraham S, Singh A, Balaji S, Mukunthan KS. From Data to Cure: A Comprehensive Exploration of Multi-omics Data Analysis

for Targeted Therapies. Mol Biotechnol. 2025 Apr;67(4):1269–89.

51. Rowland A, van Dyk M, Mangoni AA, Miners JO, McKinnon RA, Wiese MD, et al. Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure. Expert Opin Drug Metab Toxicol. 2017 Jan;13(1):31–49.
52. Koo SH, Lo YL, Yee JY, Lee EJ. Genetic and/or non-genetic causes for inter-individual and inter-cellular variability in transporter protein expression: implications for understanding drug efficacy and toxicity. Expert Opin Drug Metab Toxicol. 2015;11(12):1821–37.
53. Roichman A, Zuo Q, Hwang S, Lu W, Cordova RA, MacArthur MR, et al. Microbiome metabolism of dietary phytochemicals controls the anticancer activity of PI3K inhibitors. Cell. 2025 May 29;188(11):3065–80.e21.
54. Tolcher AW, Peng W, Calvo E. Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors. Mol Cancer Ther. 2018 Jan;17(1):3–16.
55. Liang Y, Wang L, Ma P, Ju D, Zhao M, Shi Y. Enhancing anti-tumor immune responses through combination therapies: epigenetic drugs and immune checkpoint inhibitors. Front Immunol. 2023 Nov 23;14:1308264.
56. Ahammed MS, Wang X. Promoting proteostasis by cAMP/PKA and cGMP/PKG. Trends Mol Med. 2025 Mar;31(3):224–39.
57. Sharma A, Madhunapantula SV, Robertson GP. Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems. Expert Opin Drug Metab Toxicol. 2012 Jan;8(1):47–69.
58. Tripathi D, Pandey P, Sharma S, Rai AK, Prabhu B H M. Advances in nanomaterials for precision drug delivery: Insights into pharmacokinetics and toxicity. Bioimpacts. 2024 Nov 2;15:30573.
59. Kamala GR. Design, Classification, and Therapeutic Applications of Prodrugs in Modern Drug Development. Journal of Pharma Insights and Research. 2025 Aug 5;3(4):102–10.
60. Miljković F, Bajorath J. Kinase Drug Discovery: Impact of Open Science and Artificial Intelligence. Mol Pharm. 2024 Oct 7;21(10):4849–59.
61. Elgawish MS, Almatary AM, Zaitone SA, Salem MSH. Leveraging artificial intelligence and machine learning in kinase inhibitor development: advances, challenges, and future prospects. RSC Med Chem. 2025 Aug 12;16(10):4698–720.
62. Hakami MA. Harnessing machine learning potential for personalised drug design and overcoming drug resistance. J Drug Target. 2024 Sep;32(8):918–30.
63. Marques L, Costa B, Pereira M, Silva A, Santos J, Saldanha L, et al. Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare. Pharmaceutics. 2024 Feb 27;16(3):332.
64. Marchetti M. Cost-effectiveness of kinase inhibitors for hematologic malignancies: a systematic and critical review. Expert Rev Pharmacoecon Outcomes Res. 2017 Oct;17(5):469–80.
65. Dupont CA, Riegel K, Pompaiah M, Juhl H, Rajalingam K. Druggable genome and precision medicine in cancer: current challenges. FEBS J. 2021 Nov;288(21):6142–58.